CTHRC1 Is Associated With Immune Escape and Poor Prognosis in Gastric Cancer

Background/Aim: Collagen triple helix repeat containing-1 (CTHRC1) promotes tumor progression by regulating the immunosuppression of the tumor microenvironment. However, the function of CTHRC1 in gastric cancer (GC) and its relationship with tumor-infiltrating immune cells remains unclear. Patients and Methods: Data were downloaded from The Cancer Genome Atlas (TCGA) database. The difference in expression of CTHRC1 in GC and adjacent non-tumor tissues was analyzed by R software and verified by the online database Oncomine. A Kaplan–Meier survival analysis was selected for evaluating the impact of CTHRC1 expression on the survival of GC and verified by the Kaplan–Meier plotter. The relationship between CTHRC1 expression and clinicopathological parameters was assessed by univariate and multivariate Cox regression. The correlation with tumor-infiltrating immune cells was analyzed by Tumor Immune Estimation Resource (TIMER). A gene set enrichment analysis (GSEA) was used to screen the signaling pathways between low and high CTHRC1 expression datasets. Results: The expression of CTHRC1 in GC tissue was higher than that in adjacent non-tumor tissues. The Kaplan–Meier curve showed that patients with higher CTHRC1 expression had a worse prognosis. The univariate and multivariate Cox analyses showed that high expression of CTHRC1 was an important independent predictor of poor overall survival in GC. The TIMER database analysis revealed that CTHRC1 was associated with five tumor immunosuppressive cells in GC. The GSEA indicated that 10 signaling pathways were enriched in samples with a high CTHRC1 expression phenotype. Conclusion: CTHRC1 might be a new prognostic biomarker for CG and might be a potential target for treatment of GC.